ਛਾਤੀ ਦਾ ਕੈਂਸਰ
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
ਕਿੱਥੇ ਜਾਣਾ ਹੈ
ਇਸ ਟਰਾਇਲ ਲਈ ਭਾਰਤ ਵਿੱਚ 10 ਹਸਪਤਾਲ ਮਰੀਜ਼ਾਂ ਨੂੰ ਲੈ ਰਹੇ ਹਨ।
ਰਜਿਸਟਰੀ ਸਮਰੀ (ਤਕਨੀਕੀ)
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positive breast cancer cells have proteins on their surface called receptors that bind to hormones like estrogen and progesterone (female sex hormones). These hormones can promote the growth of cancer cells. HER2-negative describes cells that have a small amount or none of a protein called HER2 on their surface. In normal cells, HER2 helps control cell growth. Ca…
ਸਪੌਂਸਰ: ਫਾਈਜ਼ਰ
NCT07062965 on ClinicalTrials.gov
ਰਜਿਸਟਰੀ ਵਿੱਚ ਆਖਰੀ ਵਾਰ 19 ਅਕਤੂਬਰ 2026 ਨੂੰ ਅਪਡੇਟ ਕੀਤਾ ਗਿਆ · ਅਸੀਂ 20 ਅਕਤੂਬਰ 2026 ਨੂੰ ਪੜ੍ਹਿਆ